Hyponatremia Impairs Early Posttransplantation Outcome in Patients with Cirrhosis Undergoing Liver Transplantation
Overview
Authors
Affiliations
Background & Aims: Hyponatremia is associated with reduced survival in patients with cirrhosis awaiting liver transplantation. However, it is not known whether hyponatremia also represents a risk factor of poor outcome after transplantation. We aimed to assess the effects of hyponatremia at the time of transplantation on posttransplantation outcome in patients with cirrhosis.
Methods: Two-hundred forty-one consecutive patients with cirrhosis submitted to liver transplantation during a 4-year period (January 2000-December 2003) were included in the study. The main end point was survival at 3 months after transplantation. Secondary end points were complications within the first month after transplantation.
Results: Patients with hyponatremia (serum sodium lower than 130 mEq/L) had a greater incidence of neurologic disorders, renal failure, and infectious complications than patients without hyponatremia (odds ratio; 4.6, 3.4 and 2.7, respectively) within the first month after transplantation. By contrast, hyponatremia was not associated with an increased incidence of severe intra-abdominal bleeding, acute rejection, or vascular and biliary complications. Hyponatremia was an independent predictive factor of early posttransplantation survival. Three-month survival of patients with hyponatremia was 84% compared with 95% of patients without hyponatremia (P < .05). Survival was similar after 3 months.
Conclusions: In patients with cirrhosis, the presence of hyponatremia is associated with a high rate of neurologic disorders, infectious complications, and renal failure during the first month after transplantation and reduced 3-month survival. In cirrhosis, hyponatremia should be considered not only a risk factor of death before transplantation but also a risk factor of impaired early posttransplantation outcome.
Kang M, Koh H, Kim D, Yim S, Choi M, Min E Transpl Int. 2024; 37:12342.
PMID: 38476214 PMC: 10930032. DOI: 10.3389/ti.2024.12342.
Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review.
Verona P, Edwards J, Hubert K, Avorio F, Lo Re V, Di Stefano R Drug Saf. 2024; 47(5):419-438.
PMID: 38353884 DOI: 10.1007/s40264-024-01398-5.
Evidence-based hyponatremia management in liver disease.
Ryu J, Baek S, Kim S Clin Mol Hepatol. 2023; 29(4):924-944.
PMID: 37280091 PMC: 10577348. DOI: 10.3350/cmh.2023.0090.
Teo C, Gan M, Tay R, Loh W, Loh N J Clin Endocrinol Metab. 2022; 108(5):1254-1271.
PMID: 36472931 PMC: 10099166. DOI: 10.1210/clinem/dgac685.
Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.
Praharaj D, Anand A J Clin Exp Hepatol. 2022; 12(2):575-594.
PMID: 35535075 PMC: 9077240. DOI: 10.1016/j.jceh.2021.09.008.